This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Mithra Pharmaceuticals Future Growth
Future criteria checks 5/6
Mithra Pharmaceuticals is forecast to grow earnings and revenue by 32.4% and 26.3% per annum respectively. EPS is expected to grow by 42.8% per annum. Return on equity is forecast to be 13.6% in 3 years.
Key information
32.4%
Earnings growth rate
42.75%
EPS growth rate
Pharmaceuticals earnings growth
14.4%
Revenue growth rate
26.3%
Future return on equity
13.55%
Analyst coverage
Low
Last updated
n/a
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
OTCPK:MITP.F - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2024
184
64
42
78
4
12/31/2023
128
-33
-6
-12
4
12/31/2022
150
65
67
126
4
6/30/2022
22
-93
-99
-76
N/A
3/31/2022
22
-105
-97
-75
N/A
12/31/2021
23
-117
-96
-74
N/A
9/30/2021
21
-115
-93
-74
N/A
6/30/2021
19
-113
-91
-73
N/A
3/31/2021
14
-103
-94
-77
N/A
12/31/2020
9
-92
-96
-80
N/A
9/30/2020
44
-31
-85
-70
N/A
6/30/2020
79
29
-73
-59
N/A
3/31/2020
88
1
-68
-53
N/A
12/31/2019
97
-27
-62
-47
N/A
9/30/2019
84
-54
-42
-28
N/A
6/30/2019
71
-82
-21
-5
N/A
3/31/2019
64
-55
-14
-1
N/A
12/31/2018
58
-28
-7
4
N/A
9/30/2018
46
-41
-23
-9
N/A
6/30/2018
33
-53
-40
-25
N/A
3/31/2018
33
-46
-44
-28
N/A
12/31/2017
32
-38
-47
-31
N/A
9/30/2017
26
-37
-47
-32
N/A
6/30/2017
20
-36
-46
-32
N/A
3/31/2017
21
-36
-43
-28
N/A
12/31/2016
22
-35
-40
-23
N/A
9/30/2016
21
-29
-35
-23
N/A
6/30/2016
20
-23
-31
-22
N/A
3/31/2016
20
-16
N/A
-20
N/A
12/31/2015
20
-10
N/A
-18
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MITP.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MITP.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MITP.F is expected to become profitable in the next 3 years.
Revenue vs Market: MITP.F's revenue (26.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: MITP.F's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MITP.F's Return on Equity is forecast to be low in 3 years time (13.6%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2022/12/05 13:59
End of Day Share Price
2022/09/07 00:00
Earnings
2022/06/30
Annual Earnings
2021/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mithra Pharmaceuticals SA is covered by 2 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.